James Noble is Director at GW PHARMACEUTICALS PLC (GWPH). They have made 5 open-market trades across 3 companies since 2007, most recently 2021-05-05.
CIK 0001388000
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $57K since 2007, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADAP | SELL | 2020-05-29 | 2020-06-02 | $9.33 | $4.7M | -12.8% | -14.1% | -23.7% |
| ADAP | SELL | 2020-01-13 | 2020-01-15 | $4.67 | $1.4M | -5.3% | -3.8% | -17.5% |
| GWPH | SELL | 2019-05-24 | 2019-05-29 | $15.32 | $1.3M | -3.6% | -4.7% | -23.6% |
| GWPH | SELL | 2019-05-24 | 2019-05-29 | $15.26 | $638K | -3.6% | -4.7% | -23.6% |
| CRGN | BUY | 2007-05-08 | 2007-05-09 | $2.87 | $57K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.